The following statement is attributable to:

Bobby Mukkamala, MD

Chair, AMA Substance Use and Pain Care Task Force

“The American Medical Association (AMA) applauds the Drug Enforcement Administration’s (DEA) decision (PDF) to extend flexibilities in the prescribing of controlled substances through telehealth patient visits through Nov. 11, 2023. These medications, including those used to treat opioid use disorder, are a vital form of care for millions of Americans who have come to rely on safe and effective telemedicine appointments.

“Patients being treated with these medications often have challenges securing and traveling to in-person appointments. We are grateful the DEA is approaching this issue with the gravity it deserves.”

Note: This statement was updated May 9, 2023.

Media Contact:

AMA Media & Editorial

ph: (312) 464-4430

[email protected]

About the American Medical Association

The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care.  The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.